Media Summary: A gene-editing therapy for sickle cell disease was Lecanemab, known as the brand name Leqembi, is the The Food and Drug Administration has just
U S Fda Approves First - Detailed Analysis & Overview
A gene-editing therapy for sickle cell disease was Lecanemab, known as the brand name Leqembi, is the The Food and Drug Administration has just CNBC's Annika Kim Constantino reports on the The Food and Drug Administration on Thursday